Ilmarinen Mutual Pension Insurance Co Invests $3.03 Million in argenex SE $ARGX

Ilmarinen Mutual Pension Insurance Co acquired a new stake in shares of argenex SE (NASDAQ:ARGX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,600 shares of the company’s stock, valued at approximately $3,027,000.

Other hedge funds have also made changes to their positions in the company. Abound Wealth Management increased its holdings in shares of argenex by 3,200.0% during the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after acquiring an additional 32 shares during the last quarter. Sound Income Strategies LLC acquired a new position in shares of argenex during the 4th quarter valued at about $28,000. Ameriflex Group Inc. acquired a new position in shares of argenex during the 3rd quarter valued at about $32,000. Aventura Private Wealth LLC acquired a new position in argenex in the 4th quarter valued at $38,000. Finally, Sunbelt Securities Inc. acquired a new position in argenex in the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Trading Down 0.3%

Shares of NASDAQ:ARGX opened at $835.99 on Friday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The firm has a market capitalization of $51.99 billion, a PE ratio of 37.22, a PEG ratio of 1.33 and a beta of 0.46. The business’s 50 day moving average is $779.30 and its 200-day moving average is $815.27.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%.The company had revenue of $1.31 billion for the quarter. On average, sell-side analysts predict that argenex SE will post 25.27 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Citizens Jmp raised their target price on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research note on Friday, February 27th. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. Guggenheim raised their target price on argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a report on Friday, May 8th. Oppenheimer lowered their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Finally, Royal Bank Of Canada lowered their target price on argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a report on Friday, February 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,017.78.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.